Medicinska fakulteten

1. Vasoactive intestinal peptide rescues cultured rat myenteric neurons from lipopolysaccharide induced cell death

   MB Arciszewski, Elin Sand & Eva Ekblad, 2008, I: Regulatory Peptides. 146, 1-3, s. 218-223

   Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

2. Vasoactive intestinal polypeptide and acetylcholine coexist with neuropeptide Y, dopamine-beta-hydroxylase, tyrosine hydroxylase, substance P or calcitonin gene-related peptide in neuronal subpopulations in cranial parasympathetic ganglia of rat

   J E Hardebo, N Suzuki, E Ekblad & Christer Owman, 1992, I: Cell and Tissue Research. 267, 2, s. 291-300

   Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

3. Vasoactive intestinal polypeptide in the PMSG-primed immature rat ovary and its effect on ovulation in the isolated rat ovary perfused in vitro

   G Schmidt, J Jörgensen, P Kannisto, F Liedberg, B Ottesen & Christer Owman, 1990, I: Journal of Reproduction & Fertility. 90, 2, s. 465-472

   Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

4. Vasoactive peptides associate with treatment outcome ofbevacizumab-containing therapy in metastatic colorectal cancer

   Helga Hagman, Pär-Ola Bendahl, Olle Melander, Jan Sundberg, Anders Johnsson & Mattias Belting, 2017, I: Acta Oncologica. 56, 5, s. 653-660

   Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

5. Vasoactive peptides in the skin.

   Joanna Wallengren, 1997, I: Journal of Investigative Dermatology Symposium Proceedings. 2, 1, s. 49-55

   Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

6. Vasoactive peptides in the skin.

   Joanna Wallengren, 1998 okt 7, s. S73.

   Forskningsoutput: Konferensbidrag › Konferensabstract

7. Vasoactive Peptides with Angiogenesis-Regulating Activity Predict Cancer Risk in Males.

   Mattias Belting, Peter Almgren, Jonas Manjer, Bo Hedblad, Joachim Struck, Thomas J Wang, Andreas Bergmann & Olle Melander, 2012, I: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 21, 3, s. 513-522

   Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

8. Vasoconstrictor effects in spinal cord of the substance P antagonist [D-Arg, D-Trp7,9 Leu11]-substance P (Spantide) and somatostatin and interaction with thyrotropin releasing hormone

   J Freedman, C Post, J Kåhrström, A Öhlen, P Mollenholt, Christer Owman, L Alari & T Hökfelt, 1988, I: Neuroscience. 27, 1, s. 267-278

   Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

9. Vasodilation effect of atropine on rat mesenteric artery

   Jianpu Zheng, Y X Cao, Cang-Bao Xu & Lars Edvinsson, 2005, I: Yao Xue Xue Bao. 40, 5, s. 402-405

   Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

10. Vasodilator actions of EDHF and anandamide

    David Andersson, 2001, Department of Clinical Pharmacology, Lund University Hospital. 86 s.

    Forskningsoutput: Avhandling › Doktorsavhandling (sammanläggning)

11. Vasodilator effect of endothelin in cutaneous microcirculation of heart failure patients.

    Sven E Andersson, Marie-Louise Edvinsson, Kjell Alving & Lars Edvinsson, 2005, I: Basic & Clinical Pharmacology & Toxicology. 97, 2, s. 80-85

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

12. Vasogen's immune modulation therapy (IMT) improves postischemic foot skin blood flow and transcutaneous pO(2) recovery rates in patients with advanced peripheral arterial occlusive disease.

    Lars Edvinsson, M L Edvinsson & G Angus Deveber, 2003, I: International Angiology. 22, 2, s. 141-147

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

13. Vasomotor menopausal symptoms are associated with increased risk of coronary heart disease.

    Gerrie-Cor M Gast, Victor J M Pop, Göran Samsioe, Diederick E Grobbee, Peter M Nilsson, Jules J Keyzer, Colette J M Wijnands-van Gent & Yvonne T van der Schouw, 2011, I: Menopause. 18, s. 146-151

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

14. Vasomotor symptoms are associated with a lower bone mineral density.

    Gerrie-Cor Gast, Diederick Grobbee, Victor Pop, Jules Keyzer, Colette Wijnands-van Gent, Göran Samsioe, Peter Nilsson & Yvonne van der Schouw, 2009, I: Menopause. 16, s. 231-238

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

15. Vasomotor Symptoms Are Associated with an Adverse Cardiovascular Risk Profile

    Gerrie-Cor M. Gast, Göran Samsioe, Diederick E. Grobbee, Peter M. Nilsson & Yvonne T. van der Schouw, 2009, I: Circulation. 119, 10, s. E317-E317

    Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract

16. Vasomotor symptoms, estradiol levels and cardiovascular risk profile in women.

    Gerrie-Cor M Gast, Göran Samsioe, Diederick E Grobbee, Peter Nilsson & Yvonne T van der Schouw, 2010, I: Maturitas. Mar 4, s. 285-290

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

17. Vasopeptidase inhibition with omapatrilat increases fluid and protein microvascular permeability in cat skeletal muscle.

    Johan Persson, Peter Morsing & Per-Olof Grände, 2004, I: Journal of Hypertension. 22, 3, s. 637-644

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

18. Vasopressin: novel roles for a new hormone – Emerging therapies in cardiometabolic and renal diseases

    O. Melander, 2017 okt 1, I: Journal of Internal Medicine. 282, 4, s. 281-283

    Forskningsoutput: Tidskriftsbidrag › Översiktsartikel

19. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats

    Christopher Taveau, Catherine Chollet, Ludovic Waeckel, Dorinne Desposito, Daniel G. Bichet, Marie-Francoise Arthus, Christophe Magnan, Erwann Philippe, Valerie Paradis, Fabienne Foufelle, Isabelle Hainault, Sofia Enhörning, Gilberto Velho, Ronan Roussel, Lise Bankir, Olle Melander & Nadine Bouby, 2015, I: Diabetologia. 58, 5, s. 1081-1090

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

20. Vasopressin and oxytocin in normal reproduction and in the patophysiology of preterm labour and primary dysmenorrhoea. Development of receptor antagonists for therapeutic use in these conditions.

    Mats Åkerlund, 2004, I: Akademia Medyczna w Białymstoku. 49, s. 18-21

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

21. Vasopressin, cardiorenal disease and hydration. The vasopressin system in relation to the risk of cardiorenal disease and how vasopressin levels are affected by salt and water interventions in humans.

    Irina Tasevska, 2017, Lund: Lund University: Faculty of Medicine. 76 s.

    Forskningsoutput: Avhandling › Doktorsavhandling (sammanläggning)

22. Vasopressin, from regulator to disease predictor for diabetes and cardiometabolic risk

    Olle Melander, 2016 jun 14, I: Annals of Nutrition and Metabolism. 68, 2, s. 24-28 5 s.

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

23. Vasopressin-induced mouse urethral contraction is modulated by caveolin-1.

    Jianwen Zeng, Mari Ekman, Mario Grossi, Daniel Svensson, Bengt-Olof Nilsson, Chonghe Jiang, Bengt Uvelius & Karl Swärd, 2015, I: European Journal of Pharmacology. 750, s. 59-65

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

24. Vasopressin induces endolymphatic hydrops in mouse inner ear, as evaluated with repeated 9.4 T MRI.

    Eva Degerman, René in 't Zandt, Ann-Kristin Holmén-Pålbrink & Måns Magnusson, 2015, I: Hearing Research. 330, Part A, s. 119-124

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

25. Vasopressin receptor mRNA expression in the human gastrointestinal tract

    H-J Monstein, M Truedsson, A Ryberg & Bodil Ohlsson, 2008, I: European Surgical Research. 40, 1, s. 34-40

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift